SORAFENIB

SynDRA canonical compound SYN0005358 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	BRAF
Mechanism of action	RET tyrosine kinase inhibitor
Indication	hepatocellular carcinoma (HCC) \| renal cell carcinoma (RCC) \| thyroid cancer
Disease area	oncology

All known targets

NEXAVAR
Nexavar
SORAFENIB TOSYLATE
BAY 43-9006
BAY-545-9085
sorafenib tosilate
nexavar
sorafenib tosylate
BAY-43-9006
Sorafenibum
Sorafenib [INN]
Nexavar (TN)
Sorafenib (INN)
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
Sorafenib (Pan-TK inhibitor)
4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE
sorafenibum
Sorafenib free base
284461-73-0 (free base)
MFCD06411450
9ZOQ3TZI87
CHEMBL1336
DTXSID7041128
CHEBI:50924
Sorafenib (Nexavar)
Donafenib (Sorafenib D3)
2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
BAX
NSC-724772
NCGC00167488-01
UNII-9ZOQ3TZI87
Sorafenib [USAN:INN:BAN]